Description: RepliCel Life Sciences Inc. is a regenerative medicine company focused on developing autologous cell therapies that treat functional cellular deficits. The Company's product pipeline includes RCT-01-Tendon Repair, RCS-01-Skin Rejuvenation, RCH-01-Hair Regeneration and RCI-02-Dermal Injector. RCT-01 is an autologous cell-based treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle sheath to treat chronic tendinosis caused by acute and chronic tensile overuse. RCH-01 also utilizes dermal sheath cup cells isolated from the hair follicle to treat androgenetic alopecia. RCI-02 is a dermal injector designed to control intradermal (dermis), subcutaneous (fat) or intramuscular injections. It is designed to support the injection of RCH-01 and RCS-01 cell therapy products. The injector has applications for dermatological procedures requiring injections of specific volumes of material at specific depths, including cellular products, fillers and collagen injections.
Home Page: www.replicel.com
RP Technical Analysis
570 Granville Street
Vancouver,
BC
V6C 3P1
Canada
Phone:
NA
Officers
| Name | Title |
|---|---|
| Mr. Andrew Schutte | Pres, CEO & Director |
| Dr. Kevin John McElwee Ph.D. | Co-Founder & Chief Scientific Officer |
| Mr. Simon S. Ma B.A., CPA, CA | Chief Financial Officer |
| Dr. Rolf Hoffmann M.D. | Chief Medical Officer & Member of Clinical Advisory Board |
| Mr. R. Lee Buckler B.Ed., L.L.B., LLB | Corp. Sec. & Director |
| Ben Austring | Chief Legal Officer & Operations Mang. |
| Mr. Darrell Panich M.Sc, PMP, CPM | Clinical Consultant |
Exchange: V
Country: CA : Canada
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 10.8767 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |